Rhumbline Advisers Acquires Shares of 45,197 Renovaro Inc. (NASDAQ:RENB)

Rhumbline Advisers acquired a new stake in shares of Renovaro Inc. (NASDAQ:RENB – Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 45,197 shares of the company’s stock, valued at approximately $79,000. A number of other hedge funds and other institutional investors have also recently made [...]

featured-image

Rhumbline Advisers acquired a new stake in shares of Renovaro Inc. ( NASDAQ:RENB – Free Report ) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 45,197 shares of the company’s stock, valued at approximately $79,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in RENB. SG Americas Securities LLC purchased a new position in shares of Renovaro during the first quarter valued at approximately $46,000. Tidal Investments LLC bought a new position in Renovaro during the 1st quarter valued at approximately $98,000.



Bank of New York Mellon Corp purchased a new position in Renovaro during the second quarter valued at $220,000. Finally, Vanguard Group Inc. raised its holdings in Renovaro by 904.

0% in the first quarter. Vanguard Group Inc. now owns 3,916,672 shares of the company’s stock worth $10,379,000 after buying an additional 3,526,565 shares during the last quarter.

Hedge funds and other institutional investors own 71.41% of the company’s stock. Renovaro Trading Down 2.

0 % Renovaro stock opened at $0.48 on Tuesday. Renovaro Inc.

has a 12 month low of $0.42 and a 12 month high of $5.25.

The stock has a fifty day simple moving average of $0.68 and a two-hundred day simple moving average of $1.41.

The firm has a market cap of $71.29 million, a price-to-earnings ratio of -0.62 and a beta of 0.

58. Insider Activity at Renovaro About Renovaro ( Free Report ) Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.

Featured Articles Five stocks we like better than Renovaro Which Wall Street Analysts are the Most Accurate? TJX Stock: A Buying Opportunity Before the Holiday Rush What Are Dividends? Buy the Best Dividend Stocks Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge What Are Growth Stocks and Investing in Them Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth Receive News & Ratings for Renovaro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renovaro and related companies with MarketBeat.com's FREE daily email newsletter ..